Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium

References

• Flach AJ. Topical nonsteroidal antiinflammatory drugs in ophthalmology. Int Ophthalmol Clin 2002;42:1–11
   PubMedGoogle Scholar
• Samiy N, Foster CS. The role of nonsteroidal antiinflammatory drugs in ocular inflammation. Int Ophthalmol Clin 1996;36: 195–206
   PubMedGoogle Scholar
• Koay P. The emerging roles of topical non-steroidal anti-inflammatory agents in ophthalmology. Br J Ophthalmol 1996;80:480–5
   PubMed Web of Science ®Google Scholar
• Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 2004;18: 790–804
   PubMed Web of Science ®Google Scholar
• Malhotra S, Shafiq N, Pandhi P. COX-2 inhibitors: a class act or just vigorously promoted. MedGenMed 2004;6: 6
   Google Scholar
• Scott TE. Pharmaceutical agents for the treatment of rheumatoid arthritis. Manag Care 2001;10(Suppl):2–9
   Google Scholar
• Boelsterli UA. Mechanisms of NSAID-induced hepatotoxicity: focus on nimesulide. Drug Saf 2002;25:633–48
   PubMed Web of Science ®Google Scholar
• Fry SW, Seeff LB. Hepatotoxicity of analgesics and anti-inflammatory agents. Gastroenterol Clin North Am 1995;24: 875–905
   PubMed Web of Science ®Google Scholar
• FDA Public Health Advisory. FDA announces important changes and additional warnings for COX-2 selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). Available from http://www.fda.gov/cder/drug/advisory/COX2.htm [Last accessed 17 Aug 2005]
   Google Scholar
• Schuman JS. Short- and long-term safety of glaucoma drugs. Expert Opin Drug Saf 2002;1:181–94
   PubMedGoogle Scholar
• Fraunfelder FT, Morgan RL, Yunis AA. Blood dyscrasias and topical ophthalmic chloramphenicol. Am J Ophthalmol 1993;115:812–3
   PubMedGoogle Scholar
• Flach AJ, Dolan BJ, Irvine AR. Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. Am J Ophthalmol 1987;103: 479–86
   Google Scholar
• Flach AJ, Jampol LM, Weinberg D, et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. Am J Ophthalmol 1991;112:514–19
   PubMed Web of Science ®Google Scholar
• Flach AJ, Lavelle CJ, Olander KW, et al. The effect of ketorolac tromethamine solution 0.5% in reducing postoperative inflammation after cataract extraction and intraocular lens implantation. Ophthalmology 1988;95:1279–84
   Google Scholar
• Flach AJ, Stegman RC, Graham J, et al. Prophylaxis of aphakic cystoid macular edema without corticosteroids. A paired-comparison, placebo-controlled double-masked study. Ophthalmology 1990;97:1253–8
   Google Scholar
• Simone JN, Pendelton RA, Jenkins JE. Comparison of the efficacy and safety of ketorolac tromethamine 0.5% and prednisolone acetate 1% after cataract surgery. J Cataract Refract Surg 1999;25: 699–70
   Google Scholar
• Heier J, Cheetham JK, Degryse R, et al. Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate to severe ocular inflammation after cataract surgery: A randomized, vehicle-controlled clinical trial. Am J Ophthalmol 1999;127: 253–9
   Google Scholar
• Solomon KD, Cheetham JK, DeGryse R, et al. Topical ketorolac tromethamine 0.5% ophthalmic solution in ocular inflammation after cataract surgery. Ophthalmology 2001;108:331–7
   Google Scholar
• Donshik PC, Pearlman D, Pinnas J, et al. Efficacy and safety of ketorolac tromethamine 0.5% and levocabastine 0.05%: a multicenter comparison in patients with seasonal allergic conjunctivitis. Adv Ther 2000;17: 94–102
   Google Scholar
• Sharma A, Gupta R, Ram J, et al. Topical ketorolac 0.5% solution for the treatment of vernal keratoconjunctivitis. Indian J Ophthalmol 1997;45:177–80
   PubMedGoogle Scholar
• Ballas Z, Blumenthal M, Tinkelman DG, et al. Clinical evaluation of ketorolac tromethamine 0.5% ophthalmic solution for the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol 1993;38(Suppl):141–8
   Google Scholar
• Tinkelman DG, Rupp G, Kaufman H, et al. Double-masked, paired-comparison clinical study of ketorolac tromethamine 0.5% ophthalmic solution compared with placebo eyedrops in the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol 1993;38(Suppl):133–40
   Google Scholar
• Srinivasan BD, Kulkarni PS. Inhibitors of the arachidonic acid cascade in the management of ocular inflammation. Prog Clin Biol Res 1989;312:229–49
   PubMedGoogle Scholar
• Snyder RW, Siekert RW, Schwiegerling J, et al. Acular® as a single agent for use as an antimiotic and anti-inflammatory in cataract surgery. J Cataract Refract Surg 2000;26:1225–7
   PubMed Web of Science ®Google Scholar
• Solomon KD, Donnenfeld ED, Raizman M, et al., for the Ketorolac Reformulation Study Groups 1 and 2. Safety and efficacy of ketorolac tromethamine 0.4% ophthalmic solution in post-photorefractive keratectomy patients. J Cataract Refract Surg 2004;30:1653–60
   Google Scholar
• ACULAR LS™ (ketorolac tromethamine ophthalmic solution) 0.4% sterile, product labeling. ©2003, Allergan, Irvine, CA, USA
   Google Scholar
• Price MO, Price FW. Efficacy of topical ketorolac tromethamine 0.4% for control of pain or discomfort associated with cataract surgery. Curr Med Res Opin 2004;20:2015–9
   Google Scholar
• Jett MF, Ramesha CS, Brown CD, et al. Characterization of the analgesic and anti-inflammatory activities of ketorolac and its enantiomers in the rat. J Pharmacol Exp Ther 1999;288: 1288–97
   PubMed Web of Science ®Google Scholar
• Pallapies D, Salinger A, Meyer zum Gottesberge A, et al. Effects of lysine clonixinate and ketorolac tromethamine on prostanoid release from various rat organs incubated ex vivo. Life Sci 1995;57:83–9
   Google Scholar
• XIBROM™ (bromfenac ophthalmic solution) 0.09%, product labeling. ©2003, Ista Pharmaceuticals, Irvine, CA, USA
   Google Scholar
• Donnenfeld E, Holland EJ, Stewart R, et al. and the Bromfenac Study Group. Topical Xibrom™ 0.1%, and investigational NSAID, significantly and rapidly decreased post-cataract surgery inflammation and reduced ocular pain. Invest Ophthalmol Vis Sci 2005;46: 791
   Google Scholar
• Miyake-Kashima M, Takano Y, Tanaka M, et al. Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis. Jpn J Ophthalmol 2004;48: 587–90
   Google Scholar
• Waterbury LD, Flach AJ. Efficacy of low concentrations of ketorolac tromethamine in animal models of ocular inflammation. J Ocul Pharmacol Ther 2004;20:345–52
   PubMed Web of Science ®Google Scholar
• Warner TD, Giuliano F, Vojnovic, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A 1999;96:7563–8
   PubMed Web of Science ®Google Scholar
• Schoenwald RD, Zhu J. The ocular pharmacokinetics of ketanserin and its metabolite, ketanserinol, in albino rabbits. J Ocul Pharmacol Ther 2000;16:481–95
   PubMed Web of Science ®Google Scholar
• Moses PL, Schroeder B, Alkhatib O, et al. Severe hepatotoxicity associated with bromfenac sodium. Am J Gastroenterol 1999;94:1393–6
   PubMed Web of Science ®Google Scholar
• Fontana RJ, McCashland TM, Benner KG, et al. Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation. The Acute Liver Failure Study Group. Liver Transpl Surg 1999;5:480–4
   PubMedGoogle Scholar
• Rabkin JM, Smith MJ, Orloff SL, et al. Fatal fulminant hepatitis associated with bromfenac use. Ann Pharmacother 1999;33:945–7
   PubMed Web of Science ®Google Scholar
• Skjodt NM, Davies NM. Clinical pharmacokinetics and pharmaco-dynamics of bromfenac. Clin Pharmacokinet 1999;36:399–408
   PubMed Web of Science ®Google Scholar
• Toradol (ketorolac tromethamine) product labeling. © 191997– 2002, Roche Laboratories, Inc
   Google Scholar
• BRONUK ophthalmic solution, product labeling. ©2003, Senju Pharmaceutical Co, Ltd, Osaka, Japan
   Google Scholar